Do class IC antiarrhythmics drugs need to be cast aside in atrial fibrillation patients with minimal coronary artery disease?
- 6 July 2022
- journal article
- editorial
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 65 (2) , 347-348
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Long-term outcomes in patients treated with flecainide for atrial fibrillation with stable coronary artery diseaseAmerican Heart Journal, 2022
- Class 1C antiarrhythmic drugs in atrial fibrillation and coronary artery diseaseJournal of Cardiovascular Electrophysiology, 2020
- 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial FibrillationJACC, 2019
- Impact of the Food and Drug Administration Approval of Flecainide and Encainide on Coronary Artery Disease Mortality: Putting Deadly Medicine to the TestThe American Journal of Cardiology, 1997
- Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutterThe American Journal of Cardiology, 1996
- Beta-blocker therapy in the cardiac arrhythmia suppression trialThe American Journal of Cardiology, 1994
- Comparison of mortality in patients treated with propafenone to those treated with a variety of antiarrhythmic drugs for supraventricular arrhythmiasThe American Journal of Cardiology, 1993
- Mortality and Morbidity in Patients Receiving Encainide, Flecainide, or PlaceboNew England Journal of Medicine, 1991
- A critical appraisal of the cardiac arrhythmia suppression trial (CAST).1991
- Propafenone for prevention of recurrent atrial fibrillationThe American Journal of Cardiology, 1988